Nexalin Technology’s Gen-2 tACS Device Shows Promise in Treating Mild Traumatic Brain Injury

Nexalin Technology, a company at the forefront of innovative medical solutions, has recently unveiled positive results from a clinical study evaluating its Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study, conducted at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs (VA) San Diego Healthcare System, as well as the Radiology, Psychiatry, and Neurosciences Departments of UC San Diego, sheds light on the potential of this groundbreaking technology.

mTBI is a significant concern for veterans and the general public, leading to various physical, cognitive, emotional, and behavioral deficits. However, effective treatments for post-concussive symptoms (PCS) have been limited, and the underlying pathophysiology is not fully understood. Symptoms of PCS often overlap with those of post-traumatic stress disorder (PTSD), further complicating diagnosis and treatment.

The clinical trial was conducted as a randomized, double-blind, placebo-controlled study over an eight-week period, involving two groups: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve sessions of either active or sham tACS over four consecutive weeks, followed by a four-week follow-up period to assess outcomes.

The positive results from this study are significant, especially considering the substantial market potential for treatments addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is projected to reach over $7.2 billion by 2032. Nexalin’s innovative approach offers promise in addressing the needs of individuals suffering from mTBI, potentially improving their quality of life and providing hope for effective treatment options in the future.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Nexalin Technology’s Gen-2 tACS Device Shows Promise in Treating Mild Traumatic Brain Injury.